Gene
APC
APC is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (75), Actionable biomarkers (1), Trial mentions (214), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention APC. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 2 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 21 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 9 of 8,738 | 0.10% | not measured | |
| 2025 | 5 of 8,875 | 0.06% | not measured | |
| 2024 | 16 of 8,597 | 0.19% | not measured | |
| 2023 | 12 of 8,275 | 0.15% | 92 of 11,460 | 0.80% |
| 2022 | 11 of 8,285 | 0.13% | 86 of 13,598 | 0.63% |
| 2021 | 13 of 8,692 | 0.15% | 133 of 15,045 | 0.88% |
| 2020 | 11 of 7,640 | 0.14% | 104 of 14,459 | 0.72% |
| 2019 | 13 of 7,300 | 0.18% | 103 of 12,159 | 0.85% |
| 2018 | 18 of 6,927 | 0.26% | 72 of 11,854 | 0.61% |
| 2017 | 10 of 6,558 | 0.15% | 83 of 11,595 | 0.72% |
Showing 10 of 37 years.
Assay-provider ledger (75)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| University of Minnesota Genomics Center | Not a company | Clinical validationAnalytical validation | 1 | April 01, 2026 |
| Dxome Co. Ltd. | Diagnostic provider | Clinical validationAnalytical validation | 1 | March 01, 2026 |
| Celemics | Diagnostic provider | Clinical validationAnalytical validation | 1 | February 10, 2026 |
| Pharos iBio Co., Ltd | Diagnostic provider | Clinical validationAnalytical validation | 1 | February 10, 2026 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 14 | September 01, 2025 +2 undated |
Showing 5 of 75 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| APC oncogenic mutation | Tankyrase Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (214)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06163365 | Trial biospecimen (AACT) |
| NCT04050345 | Trial biospecimen (AACT) |
| NCT03390907 | Trial eligibility (AACT) |
| NCT01074996 | Trial eligibility (AACT) |
| NCT02961374 | Trial eligibility (AACT) |
Showing 5 of 214 trial mentions.
Target-disease associations (1,164)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 46 XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 1,164 associations.
Vendor sourcing (804)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Frameshift: predicted to result in a loss or disruption of normal protein function through protein truncation. The predicted truncated protein may be shorten... | View ClinVar record SCV002058754.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The APC c.1A>G; p.Met1? variant (rs189807660) in transcript NM_001127511.3, also known as c.-30226A>G in transcript NM_000038.6, is not reported in the medic... | View ClinVar record SCV004562443.1 |
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Have a diagnosis of FAP with genetic testing demonstrating a pathogenic or likely pathogenic germline variant in APC, must have a clinical FAP phenotyp... | View trial NCT06578637 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | APC | View trial NCT06578637 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : ALL of the following: 1. Diagnosis of FAP i.e., at least one of following: * Genetic diagnosis: proven APC germline mutation OR * Clinical diagnos... | View trial NCT07726771 |
Showing 5 of 804 sourcing records.
Trial-cited literature (1,193)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Impact of Artificial Intelligence for Detection of Precancerous Colonic Lesions in a Fecal Immunochemical Blood Test-Based Organized Screening Program in Italy: A Randomized Control Trial. | United European gastroenterology journal | 2026 | 1 |
| Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV. | eLife | 2026 | 0 |
| Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease. | Alzheimer's & dementia : the journal of the Alzheimer's Association | 2025 | 6 |
| Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis. | Thrombosis research | 2025 | 4 |
| Evolving Biology and Therapy of WNT-Activated Medulloblastoma. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | 2 |
Showing 5 of 1,193 papers.
Protein variant mentions (964)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1002G | 1 | 2015 | PMID 25741868 |
| p.A1005V | 1 | 2015 | PMID 25741868 |
| p.A1107V | 1 | 2015 | PMID 25741868 |
| p.A1296V | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
| p.A1305T | 1 | 2015 | PMID 25741868 |
Showing 5 of 964 variants.
Human sample screening reference (12)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.E1353* | CPTAC-2 | Not Reported; Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Ductal and Lobular Neoplasms; Squamous Cell Neoplasms; Other and unspecified female genital organs; Colon; Breast; Retroperitoneum and peritoneum; Rectum; Ovary | 1 | 328 | 0.30% | 0.05% to 1.71% |
| p.E1353* | HCMI-CMDC | Ductal and Lobular Neoplasms; Complex Mixed and Stromal Neoplasms; Blood Vessel Tumors; Fibromatous Neoplasms; Epithelial Neoplasms, NOS; Mature T- and NK-Cell Lymphomas; Transitional Cell Papillomas and Carcinomas; Complex Epithelial Neoplasms; Squamous Cell Neoplasms; Soft Tissue Tumors and Sarcomas, NOS; Lymphoid Leukemias; Cystic, Mucinous and Serous Neoplasms; Gliomas; Myomatous Neoplasms; Neuroepitheliomatous Neoplasms; Malignant Lymphomas, NOS or Diffuse; Acinar Cell Neoplasms; Osseous and Chondromatous Neoplasms; Synovial-like Neoplasms; Miscellaneous Bone Tumors; Nevi and Melanomas; Adenomas and Adenocarcinomas; Other and unspecified parts of tongue; Stomach; Bronchus and lung; Larynx; Uterus, NOS; Kidney; Esophagus; Other and ill-defined sites; Skin; Colon; Thyroid gland; Bladder; Adrenal gland; Eye and adnexa; Gallbladder; Connective, subcutaneous and other soft tissues; Rectosigmoid junction; Breast; Pancreas; Small intestine; Corpus uteri; Other and unspecified parts of mouth; Liver and intrahepatic bile ducts; Nasal cavity and middle ear; Hematopoietic and reticuloendothelial systems; Brain; Other and unspecified parts of biliary tract; Bones, joints and articular cartilage of other and unspecified sites; Rectum; Unknown; Lymph nodes; Ovary | 1 | 606 | 0.17% | 0.03% to 0.93% |
| p.E1353* | TCGA-COAD | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Complex Epithelial Neoplasms; Rectosigmoid junction; Colon | 1 | 461 | 0.22% | 0.04% to 1.22% |
| p.E1353* | TCGA-READ | Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Colon; Unknown; Rectum; Rectosigmoid junction; Connective, subcutaneous and other soft tissues | 4 | 171 | 2.34% | 0.91% to 5.86% |
| p.Q1469* | TCGA-COAD | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Complex Epithelial Neoplasms; Rectosigmoid junction; Colon | 2 | 461 | 0.43% | 0.12% to 1.57% |
Showing 5 of 12 cohort observations.
Literature-extracted relations (146)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Lithium | Chemical | negative_correlate |
Apc-mutant cells act as supercompetitors in intestinal tumour initiation. | 2021 |
| Lipopolysaccharides | Chemical | associate |
Neonatal brain injury and systemic inflammation: modulation by activated protein C ex vivo. | 2015 |
| LACTIC ACID (Dermacid) | Chemical | negative_correlate |
The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome. | 2013 |
| Lycopene | Chemical | associate |
Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. | 2013 |
| Quinacrine | Chemical | positive_correlate |
Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. | 2013 |
Showing 5 of 146 relation assertions.
Organizations publishing (791)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 52 | 2009 to 2024 |
| Harvard Medical School | Academic | 41 | 2009 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 38 | 2013 to 2024 |
| The University of Texas System | Academic | 36 | 2010 to 2024 |
| Mass General Brigham | Hospital | 35 | 1997 to 2025 |
Showing 5 of 791 organizations.
Where APC appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
959 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.